FDA Gives Positive Feedback on Entera Bio's Phase 3 Protocol for Oral Osteoporosis Drug EB613
ENTX sits 46% above its 52-week low of $0.91 on light trading volume (0.3× avg).
Summary
Entera Bio received positive FDA feedback on the protocol for its 12-month registrational Phase 3 study of EB613, an oral anabolic tablet for postmenopausal osteoporosis. The FDA accepted the proposed single, randomized, placebo-controlled trial design in approximately 750 patients, with a primary endpoint of total hip bone mineral density at 12 months. This provides a clear and optimized regulatory path for the company's lead product candidate, significantly de-risking its development. This clarity is crucial for a small biotech, especially following recent capital raises and shareholder requests for increased authorized shares to fund its pipeline. Phase 3 initiation is planned for late 2026, with topline data expected in the second half of 2028.
At the time of this announcement, ENTX was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.6M. The 52-week trading range was $0.91 to $3.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.